ReproCell

ReproCell Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of ReproCell (4978.T) as of Oct 19, 2026 is 35.76. In the previous year, Net Debt to Free Cash Flow Ratio was 21.56 — a change of 65.87% (higher).

Net Debt/FCF

35.76

YoY

65.87%

Last updated:

Net Debt to Free Cash Flow Ratio of ReproCell is 2024 35.76 . Net Debt to Free Cash Flow Ratio of ReproCell was 2023 21.56 . It decreases by 65.87% higher compared to the previous year.

The ReproCell Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2017
6.35 JPY
Jan 1, 2018
8.08 JPY
Jan 1, 2019
8.71 JPY
Jan 1, 2020
6.30 JPY
Jan 1, 2021
6.38 JPY
Jan 1, 2022
15.75 JPY
Jan 1, 2023
21.56 JPY
Jan 1, 2024
35.76 JPY
The ReproCell Net Debt/FCF history
YEARNet Debt/FCFYoY
35.76+65.87%
21.56+36.87%
15.75+146.88%
6.38+1.20%
6.30-27.62%
8.71+7.74%
8.08+27.38%
6.35-23.20%
8.26+12.50%
7.35-93.77%
117.98—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Net Debt to Free Cash Flow Ratio of ReproCell is 35.76 in 2024.

Net Debt to Free Cash Flow Ratio of ReproCell changed from 21.56 to 35.76, representing a 65.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio ReproCell since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's ReproCell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ReproCell

All Key Metrics — ReproCell